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More than 100 000 human genetic variations have been described in various genes that are associated with a wide variety
of diseases. Such data provides invaluable information for both clinical medicine and basic science. A number of
locus-specific databases have been developed to exploit this huge amount of data. However, the scope, format and content
of these databases differ strongly and as no standard for variation databases has yet been adopted, the way data is pre-




Over the recent years the cloning of genes involved in com-
plex diseases such as cancer as well as the development of
new high throughput techniques like single nucleotide
polymorphism (SNP) arrays has made enormous progress.
This resulted in more than 100000 human genetic vari-
ations which have been described in various genes asso-
ciated with a wide variety of diseases (1–3). Somatic
variations in cancer are used in clinical studies and molecu-
lar pathology to characterize tumor types, to improve the
best suited treatment choice, and to predict response to
treatment. Thus, mutation analysis can play an important
role in drug discovery and drug development. Identification
of genetic variants will yield new drug targets and
biomarkers.
Cancer, as a disease of genome alterations, arises
through the sporadic acquisition of multiple somatic vari-
ations (4). However, not all mutations contribute equally to
the cancer type in which they are found. The proportion of
mutations causally implicated in cancer is still unknown
especially due to the high number of variations between
different tumors (5–9) Although the number of unique
variations for each cancer genome can be very high
(10,11), only a few somatic variations will be critical for
the development of the tumor. These causative variations,
the so-called ‘drivers’, are emerging because of selective
pressure during tumorigenesis, whereas many mutations
are only incidental or caused by genome instabilities,
so-called ‘passengers’ (12). The differentiation of disease
causing driver mutations from the passenger variations is
a challenge for mutation analysis (13).
Usefulness of mutation analysis
Analysis of mutations is useful in many ways: the study of
cancer-prone DNA repair diseases (Xeroderma pigmento-
sum, Ataxia telangiectasia, Fanconi’s anemia, Bloom’s syn-
drome and others) has given valuable insights in the
type and function of genes responsible for maintaining
DNA integrity (14–18). Mutation analysis can help to predict
the risk for developing certain types of cancer, BRCA1
and BRCA2 (increased breast cancer risk) (19) and APC
(increased risk for colon cancer) (20) being among the
best known so far.
Mutations can also influence the response of patients to
cancer drugs, e.g. the KRAS (21,22) or BRAF (23,24) muta-
tions. The presence of certain mutations can also influence
progression free or overall survival rates of patients (22,25).
Germline versus somatic mutations
In general, mutations can be grouped into two different
categories: germline and somatic. Germline mutations are
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(page number not for citation purposes)variations found in all cells of an organism including germ
line cells. They play an important role in evolution by giving
every human its genetic individuality (see SNPs) but
also give a rise to hereditary diseases like sickle-cell
anemia or phenylketonuria. Germline mutations can also
lead to increased risk for developing cancer, like BRCA1
and BRCA2 gene mutations which are associated with an
increased risk for breast and ovarian cancer (26–28).
Other examples of familial cancer syndromes include von
Hippel–Lindau syndrome (caused by mutations in VHL) (29),
Peutz–Jeghers syndrome (caused by mutations in LKB1)
(30) and Li–Fraumeni syndrome (caused by mutations in
TP53) (31).
Detection of germline mutations with current technolo-
gies is state of the art but time-consuming. Usually a large
amount of genetic material of good quality can be ex-
tracted from blood cells. However, in addition to the mu-
tation detection, the differentiation of disease causing and
neutral germline mutations having no effect on the pheno-
type is an important but non-trivial task. Currently, no gen-
erally applicable solution for this problem exists and this
question often remains unsolved.
Somatic mutations are not inherited but acquired during
lifetime in somatic cells of an organism and might cause
tissue specific tumors. An important problem with somatic
mutations is the difficulty of their detection. Tumor
samples can be very heterogeneous and are very often
‘contaminated’ with normal cells, such as stromal cells.
However, since somatic mutations are identified through
a comparison of a tumor sample with a normal sample of
the same organism the identification of the mutation is
unambiguous. Also for somatic mutations the differenti-
ation between drivers and passengers is an important but
still unsolved problem. In contrast to germline mutations
however, all somatic mutations are tumor associated.
Therefore, all non-silent somatic mutations are potential
candidates for biomarker development.
Mutation types
Genome alterations are typically classified by the mutation
type. The different databases characterize all variations
first by the effect on the nucleotide sequence: deletions,
insertions and single nucleotide variations. Mutations
occurring in the coding region of a gene can also be classi-
fied by their effect on the amino acid sequence. A variation
of the coding sequence without any change of the amino
acid sequence of the protein is called silent mutation.
Single nucleotide mutations causing the substitution of
a different amino acid are called missense mutation. A
frameshift mutation is an insertion or deletion in the
coding sequence which changes the reading frame result-
ing in a different translation of the subsequent sequence.
Nonsense mutations generate a premature stop codon and
often a non-functional truncated protein product.
SNPs versus germline mutations
Single nucleotide germline mutations and SNP are often
used as synonyms, since both describe variations of single
nucleotides, which are inherited and not tumor-associated
per se. However, concerning the databases presented here
these synonyms are used in two different meanings: SNPs
as presented in public databases like dbSNP (32,33) or
HapMap (34) are germline variations for which at most
population frequencies are known. In literature it is usual-
ly assumed that the variation should be found in more than
1% of the population in order to be called a SNP. Such
information is very useful for biomarker development
since it describes the prevalence of the mutation in differ-
ent populations. However, it is normally not possible to get
additional information (like gender, age, or disease status)
on the individuals having the SNP, only the population
a person belongs to is given. Since it is not known if the
information comes from a tumor or normal sample, a cor-
relation between diseases and SNPs cannot be calculated.
In contrast, germline mutations presented in cancer or
disease mutation databases like ‘The Cancer Genome Atlas
(TCGA)’ (35) are usually connected with additional sample
information like patient gender, age, histology or tissue.
Germline mutations are found in the normal as well as
the tumor sample. Hence, the sample information allows
for further analyses of associations between germline
mutations and diseases.
Standardization efforts
A standard problem occurring in every field where huge
amounts of data are generated is standardization.
Without standardization the task to identify and integrate
the data is very complicated, laborious, error-prone and
time-consuming. Although databases may have different
scope and aims it is important to standardize content and
annotation. The Human Genome Variation Society (HGVS)
has proposed a recommendation for the nomenclature of
genetic variations and content of mutation databases and
scientific publications (36). This naming of mutations has
now become widely accepted. Some journals (e.g. Human
Mutation) already accept only publications with mutation
notation following the HGVS proposed recommendations.
If more publishers should follow this trend it would have a
very positive effect on the usability of mutation databases
including an increase of the quality and amount of their
content.
HGVS and members have published number of recom-
mendations e.g. for the collection of somatic mutations,
sharing data, etc. There are also projects at European
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Biotechnology Information (NCBI) to develop reference
sequences, locus reference genomics (LRGs) (http://www
.lrg-sequence.org) and RefSeqGenes (http://www.ncbi.nlm
.nih.gov/projects/RefSeq/RSG/), respectively. In addition,
the Gen2Phen (http://www.gen2phen.org) project works
on data models and standards for a number of aspects
related to variation data description, storage and integra-
tion in databases.
Except for the already widely accepted naming recom-
mendations of mutations by the HGVS, a promising stand-
ardization effort for integrating all cancer genome data is
still missing.
Structure and accessibility
Historically, mutations and variations in human have been
reported only in the published literature. Mutation descrip-
tions were often not precise, no standard notation existed,
and the sequence of the reference gene under study was
almost never indicated. To this end a sophisticated muta-
tion analysis was mostly unfeasible. However, with the ex-
plosion of large-scale cancer genome sequencing (35,37–40)
more and more information on genetic variations has been
captured over the last years in publicly available databases
that can be used by clinicians or scientists as a research tool.
These databases are widespread and their scope, format
and content can be very different. Current data related to
somatic mutations is mostly buried in journals or scattered
between several locus-specific databases (LSDBs) and gen-
eral databases that have no or very limited connections
between them.
Only a few large public resources exist that comprehen-
sively compile data on somatic gene alterations in cancer:
International Agency for Research on Cancer (IARC) TP53
Database (41), Catalog of Somatic Mutations in Cancer
(COSMIC) (42), TCGA (35), Roche Cancer Genome
Database (RCGDB) and Human Gene Mutation Database
(HGMD) (43).
The LSDBs often originate as loosely organized compil-
ation of data. Since no standard system similar to the HGVS
recommendation for mutation notation has yet been estab-
lished, the presentation of the data in LSDBs varies enor-
mously. The data is mostly presented in flat files, plain text
databases, or Microsoft Excel spreadsheets making it easy
to collect and store the information, but nearly impossible
to search or retrieve specific data. More ambitious data-
bases use open source database management software
(DBMS)—like MySQL or PostgreSQL—whereas only a mi-
nority of curators use specialized software such as the
UMD (44), the Mutation Storage and Retrieval Program
(MuStaR) (45), or the Leiden Open Source Variation
Database (LOVD) (46). The use of such relational DBMSs
allows to specify complex queries and specific analyses of
customized subsets of the database.
Cancer variation databases
Currently, the best-known publicly available primary data-
base on somatic mutations in human cancer is the
‘COSMIC’(42) hosted at the Wellcome Trust Sanger institute
in Cambridge. The data is gathered from scientific publica-
tions and genome-wide screens from the Cancer Genome
Project (CGP) at the same institute. The project has been
continuously updated and improved for over 9 years and
currently contains more than 108 773 mutations in >13 500
different genes observed in over 449 676 different tumor
samples. The curation process in COSMIC is largely manual
resulting in a very high quality of the data. For each muta-
tion all details on the sample like patient age, gender, hist-
ology and tissue are available. COSMIC uses its own internal
classification system to provide tissue and histology consist-
ency within the database and to reduce redundancy.
All tissue and histology information from scientific publica-
tions is translated using this classification system. In add-
ition, for each study the project offers the information
which genes where actually screened, since published stu-
dies often focus on mutation hot spots, for example KRAS
(47), BRAF (48) or TP53 (49). This information enables
frequency data to be calculated for mutations in various
genes and different cancer types. COSMIC offers also som-
atic mutations found in cell-lines including the NCI-60 (50).
The website of COSMIC has a clear structure and is easy to
use. The interface allows to browse by gene, or search by
phenotype. Summary information on mutation counts and
frequencies are presented graphically for a better under-
standing. In addition, all information can be downloaded as
txt files, or as an Oracle dump file.
Another large mutation data source is ‘TCGA’ (35), a pro-
ject at the National Cancer Institute (NCI) and the National
Human Genome Research Institute (NHGRI). The main goal
of TCGA is to understand the molecular basis of cancer
through the application of genome analysis techniques,
including large-scale genome sequencing and SNP analysis.
For each patient a whole genome analysis of a normal, a
tumor and control samples (a second normal and tumor
sample as control) is performed enabling researchers to
distinguish between somatic and germline mutations.
All mutations found are publicly available in a special
Mutation Analysis file Format (MAF) and can be down-
loaded via the TCGA Data Portal. This portal contains all
TCGA data concerning to clinical information associated
with tumors and human subjects, genomic characteriza-
tion, and high-throughput sequencing analysis of the
tumor genomes. However, no advanced search interface
or graphical visualization of the mutation data is available.
In the starting phase the project focused on only two cancer
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Page 3 of 13types: brain cancer (glioblastoma multiforme) and ovarian
serous adenocarcinoma. After the pilot phase, which was
completed in 2009, TCGA matured to a full project and is
now dealing with more than 20 types of cancer.
Another concept focusing on the integration of hetero-
geneous mutation data sources is pursued by the RCGDB
(51), developed at Roche Pharma Research. The freely avail-
able warehouse system integrates somatic and germline
mutations gathered by manual curation from scientific
publications and public cancer mutation databases
(COSMIC, TCGA, etc.). In addition, these mutations are en-
riched by SNP data from the HapMap (34) project. Updates
are provided on a regular basis depending on the update
frequency of the external data sources (approximately
every 3 months). Access to the RCGDB is offered via a pub-
licly available web interface. A major aspect in designing
the user interface was that users should be able to search
and view mutations in an intuitive and straight-forward
manner, without having to understand the architectural
details of the warehouse system. Therefore, the database
offers a Google-like web interface to search for cancer
genome information on a single gene, sample or cell-line,
and on multiple genes, samples or cell-lines. As a special
feature the search is supported by an auto-suggestion func-
tionality allowing to search by NCBI GeneIDs, names, or
synonyms.
The HGMD (43) at the Institute of Medical Genetics in
Cardiff is a commercial mutation database providing infor-
mation on somatic and germline mutations. Furthermore,
the database offers a less up-to-date public version which
is freely available only to registered users from academic
institutions or non-profit organizations, respectively. The
data is gathered from scientific publications and from pub-
licly available LSDBs. The project claims to include all muta-
tions causing or associated with human inherited disease,
plus disease-associated/functional polymorphisms reported
in the literature. Currently, HGMD provides information
on 96 631 mutations in 3611 genes under the professional
license and 69 660 mutation in 2572 genes in the public
version of the database. The website of HGMD allows to
search by gene, publication or mutation id and presents the
results in a table view. A downloadable version of HGMD is
only available under the professional license.
In addition to multi-gene LSDBs, various single-gene
LSDBs are publicly available. The largest and best-known
single-gene LSDB is the TP53 mutation database from the
IARC (41), with all TP53 gene variations identified in human
populations and tumor samples since 1989. The database
contains information on somatic as well as germline
mutations of TP53 in patient samples, human cell-lines,
and mouse models. This data is compiled from the peer-
reviewed literature and from generalist databases. The
website offers different sophisticated interfaces for search-
ing and mining the database by multiple criteria.
Furthermore, all information can be downloaded in
tab-delimited txt-files. A large number of other single
gene databases exists like the L1CAM mutation database
from the university of Groningen (52) containing single
gene somatic mutations. Most of these LSDBs are small con-
taining mostly <500 variants.
For a detailed list of cancer mutation databases see
Table 1.
Disease variation databases
In addition to the Cancer variation database a large
number of publicly available databases focuses on disease
specific variations. An overview on such disease variation
databases can be found in Table 2.
Prominent disease mutation databases are the public
IDbases (53) maintained at the Institute of Medical
Technology, University of Tampere. The IDbases are LSDBs
for immunodeficiency-causing mutations. The project main-
tains 122 different IDBases containing altogether data for
5359 patients. In addition to gene mutations, IDbases pro-
vide information about clinical presentation. All informa-
tion has been collected from the literature as well as
directly from researchers. The databases do not provide
any sophisticated search interface and allow to download
the data as a txt-file.
Conclusion
All databases presented are good starting points to retrieve
human variation data for certain use cases depending on
the provided interfaces. However, as soon as a query gets
more complicated, an integrative approach will be neces-
sary. Unfortunately, the diversity of current mutation infor-
mation systems and the underlying data models make it
difficult to mine human variation databases in an integra-
tive approach. Currently, researchers typically have to
browse and search several databases to obtain the required
information. No unified access to all different cancer
genome related data sources exists resulting in a need for
more efficient integrative systems. With COSMIC, which is
currently integrating TCGA and IARC TP53 information, and
the RCGDB, which already integrates most of in this review
presented data sources, two promising integrative data re-
sources are available. Nevertheless, the standardization and
virtual consolidation of existing databases will be one
major challenge for future developments. Although these
problems have already been discussed in previous publica-
tions (54–56), the current situation concerning mutation
databases and their heterogeneity is still an acute problem
due to the exponential growth of data generated by
genome sequencing. This review is meant to provide an
overview on the current status of mutation data in public
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Page 4 of 13Table 1. Cancer variation database: a list of available cancer variation databases including web links
Database URL Gene(s) Mutation
type
Remark
BLMbase http://bioinf.uta.fi/BLMbase BLM Germline
CASP10base http://bioinf.uta.fi/CASP10base CASP10 Germline






















32 cancer genes Somatic,
germline














KinMutBase http://bioinf.uta.fi/KinMutBase/ Protein kinases Germline
LOVD-ATM http://www.LOVD.nl/ATM ATM Germline Uses Leiden Open
Variation Database
LOVD-B3GALTL http://www.LOVD.nl/B3GALTL B3GALTL Germline Uses Leiden Open
Variation Database
LOVD-BRCA2 http://www.LOVD.nl/BRCA2 BRCA2 Germline Uses Leiden Open
Variation Database
LOVD-FANCA http://www.LOVD.nl/FANCA FANCA Germline Uses Leiden Open
Variation Database
LOVD-FANCB http://www.LOVD.nl/FANCB FANCB Germline Uses Leiden Open
Variation Database
LOVD-FANCC http://www.LOVD.nl/FANCC FANCC Germline Uses Leiden Open
Variation Database
LOVD-FANCD2 http://www.LOVD.nl/FANCD2 FANCD2 Germline Uses Leiden Open
Variation Database
LOVD-FANCE http://www.LOVD.nl/FANCE FANCE Germline Uses Leiden Open
Variation Database
LOVD-FANCF http://www.LOVD.nl/FANCF FANCF Germline Uses Leiden Open
Variation Database
LOVD-FANCG http://www.LOVD.nl/FANCG FANCG Germline Uses Leiden Open
Variation Database
LOVD-FANCL http://www.LOVD.nl/FANCL FANCL Germline Uses Leiden Open
Variation Database
(Continued)
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Page 5 of 13Table 1. Continued
Database URL Gene(s) Mutation
type
Remark
LOVD-MUTYH http://www.LOVD.nl/MUTYH MUTYH Germline Uses Leiden Open
Variation Database
LOVD-NOTCH3 http://www.LOVD.nl/NOTCH3 NOTCH3 Germline Uses Leiden Open
Variation Database
LOVD-NROB1 http://www.LOVD.nl/NROB1 NROB1 Germline Uses Leiden Open
Variation Database
LOVD-OTC http://www.LOVD.nl/OTC OTC Germline Uses Leiden Open
Variation Database
LOVD-TSC1 http://www.LOVD.nl/TSC1 TSC1 Germline Uses Leiden Open
Variation Database














































UMD-APC http://www.umd.be/APC/ APC Germline
UMD-BRCA1 http://www.umd.be/BRCA1/ BRCA1 Germline Restricted access
UMD-BRCA2 http://www.umd.be/BRCA2/ BRCA2 Germline Restricted access
UMD-MEN1 http://www.umd.be/MEN1/ MEN1 Germline
UMD-VHL http://www.umd.be/VHL/ VHL Germline










For each database the type of mutations as well as the genes have been covered.
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Page 6 of 13Table 2. Disease variation databases: a list of available disease variation databases including web links
Database URL Gene(s) Diseases Remark
ADAbase http://bioinf.uta.fi/ADAbase ADA Adenosine deaminase deficiency
AICDAbase http://bioinf.uta.fi/AICDAbase AICDA Non-X-linked hyper-IgM
syndrome
AIREbase http://bioinf.uta.fi/AIREbase AIRE Autoimmune polyendocrinopathy




















AP3B1base http://bioinf.uta.fi/AP3B1base AP3B1 Hermansky–Pudlak syndrome 2
BIRC4base http://bioinf.uta.fi/BIRC4base BIRC4 X-linked lymphoproliferative
syndrome
BLMbase http://bioinf.uta.fi/BLMbase BLM Bloom syndrome
BLNKbase http://bioinf.uta.fi/BLNKbase BLNK BLNK deficiency
BTKbase http://bioinf.uta.fi/BTKbase BTK X-linked agammaglobulinemia
(XLA)
C1QAbase http://bioinf.uta.fi/C1QAbase C1QA C1q a polypeptide deficiency
C1QBbase http://bioinf.uta.fi/C1QBbase C1QB C1q b polypeptide deficiency
C1QCbase http://bioinf.uta.fi/C1QCbase C1QC C1q g-polypeptide deficiency
C1Sbase http://bioinf.uta.fi/C1Sbase C1S C1s deficiency
C2base http://bioinf.uta.fi/C2base C2 C2 deficiency
C3base http://bioinf.uta.fi/C3base C3 C3 deficiency
C5base http://bioinf.uta.fi/C5base C5 C5 deficiency
C6base http://bioinf.uta.fi/C6base C6 C6 deficiency
C7base http://bioinf.uta.fi/C7base C7 C7 deficiency
C8Bbase http://bioinf.uta.fi/C8Bbase C8B C8B deficiency
C9base http://bioinf.uta.fi/C9base C9 C9 deficiency
CA2base http://bioinf.uta.fi/CA2base CA2 Osteopetrosis with renal tubular
acidosis
CASP10base http://bioinf.uta.fi/CASP10base CASP10 Autoimmune lymphoproliferative
syndrome, type II







>13500 multiple tissues and histologies
CD19base http://bioinf.uta.fi/CD19base CD19 CD19 deficiency
CD247base http://bioinf.uta.fi/CD247base CD247 CD3  deficiency
CD3Dbase http://bioinf.uta.fi/CD3Dbase CD3D CD3d deficiency
CD3Ebase http://bioinf.uta.fi/CD3Ebase CD3E CD3" deficiency
CD3Gbase http://bioinf.uta.fi/CD3Gbase CD3G CD3g deficiency
CD40base http://bioinf.uta.fi/CD40base CD40 CD40 deficiency
CD40Lbase http://bioinf.uta.fi/CD40Lbase CD40L X-linked Hyper-IgM syndrome
(XHIM)
(Continued)
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Page 7 of 13Table 2. Continued
Database URL Gene(s) Diseases Remark
CD55base http://bioinf.uta.fi/CD55base CD55 Decay-accelerating factor (CD55)
deficiency
CD59base http://bioinf.uta.fi/CD59base CD59 CD59 deficiency
CD79Abase http://bioinf.uta.fi/CD79Abase CD79A Iga deficiency
CD79Bbase http://bioinf.uta.fi/CD79Bbase CD79B Igb deficiency
CD8Abase http://bioinf.uta.fi/CD8Abase CD8A CD8a deficiency
CEBPEbase http://bioinf.uta.fi/CEBPEbase CEBPE Neutrophil-specific granule
deficiency
CFDbase http://bioinf.uta.fi/CFDbase CFD Factor D deficiency
CFHbase http://bioinf.uta.fi/CFHbase CFH Factor H deficiency
CFIbase http://bioinf.uta.fi/CFIbase CFI Complement factor I deficiency
CFPbase http://bioinf.uta.fi/CFPbase CFP Properdin deficiency
CIITAbase http://bioinf.uta.fi/CIITAbase CIITA MHCII transactivating protein
deficiency
CLCN7base http://bioinf.uta.fi/CLCN7base CLCN7 Autosomal dominant
osteopetrosis, type 2
CTSCbase http://bioinf.uta.fi/CTSCbase CTSC Papillon-Lefevre syndrome
CXCR4base http://bioinf.uta.fi/CXCR4base CXCR4 WHIM syndrome
CYBAbase http://bioinf.uta.fi/CYBAbase CYBA Autosomal recessive p22phox
deficiency
CYBBbase http://bioinf.uta.fi/CYBBbase CYBB X-linked chronic granulomatous
disease (XCGD)
DCLRE1Cbase http://bioinf.uta.fi/DCLRE1Cbase DCLRE1C Artemis deficiency
DKC1base http://bioinf.uta.fi/DKC1base DKC1 Hoyeraal-Hreidarsson syndrome
DNMT3Bbase http://bioinf.uta.fi/DNMT3Bbase DNMT3B ICF syndrome
ELA2base http://bioinf.uta.fi/ELA2base ELA2 Cyclic neutropenia; Congenital
neutropenia












FASLGbase http://bioinf.uta.fi/FASLGbase FASLG Autoimmune lymphoproliferative
syndrome, type 1B (ALPS1B)
FCGR1Abase http://bioinf.uta.fi/FCGR1Abase FCGR1A CD64 deficiency
FCGR3Abase http://bioinf.uta.fi/FCGR3Abase FCGR3A Natural killer cell deficiency
FH aHUS Mutation
Database
http://www.fh-hus.org/ CFH Hemolytic uraemic syndrome
(HUS)
FOXN1base http://bioinf.uta.fi/FOXN1base FOXN1 T-cell immunodeficiency, congeni-
tal alopecia, and nail dystrophy
FOXP3base http://bioinf.uta.fi/FOXP3base FOXP3 Immunodysregulation, polyendo-
crinopathy, and enteropathy,
X-linked; IPEX




HAEdb http://hae.enzim.hu/ SERPING1 Hereditary angioedema
HAX1base http://bioinf.uta.fi/HAX1base HAX1 Severe congenital neutropenia
(Kostmann disease)
(Continued)
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Database URL Gene(s) Diseases Remark
ICOSbase http://bioinf.uta.fi/ICOSbase ICOS ICOS deficiency
IFNGR1base http://bioinf.uta.fi/IFNGR1base IFNGR1 IFNg1-receptor deficiency
IFNGR2base http://bioinf.uta.fi/IFNGR2base IFNGR2 IFNg2-receptor deficiency
IGHG2base http://bioinf.uta.fi/IGHG2base IGHG2 IgG2 deficiency
IGHMbase http://bioinf.uta.fi/IGHMbase IGHM m heavy chain deficiency
IGLL1base http://bioinf.uta.fi/IGLL1base IGLL1  5surrogate light-chain deficiency
IKBKGbase http://bioinf.uta.fi/IKBKGbase IKBKG Nemo deficiency
IL12Bbase http://bioinf.uta.fi/IL12Bbase IL12B Interleukin-12 (IL12) p40
deficiency
IL12RB1base http://bioinf.uta.fi/IL12RB1base IL12RB1 Interleukin-12 receptor b1
deficiency
IL2RAbase http://bioinf.uta.fi/IL2RAbase IL2RA Interleukin-2 receptor a deficiency
IL2RGbase http://research.nhgri.nih.gov/scid/ IL2RG X-linked SCID
IL7Rbase http://bioinf.uta.fi/IL7Rbase IL7R Interleukin-7 receptor a deficiency
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ LPIN2 Majeed syndrome
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ MEFV Familial Mediterranean fever
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ MVK Hyper IgD Syndrome and periodic
fever
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ NLRP3 Familial cold autoinflammatory
syndrome, Muckle-Wells
syndrome and chronic infantile
neurological cutaneous and
articular syndrome
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ NLRP7 Recurrent Hydatidiform moles
and reproductive wastage
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ NOD2 Blau syndrome, Chrohn’s disease,
early onset sarcoidosis
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ PSTPIP1 Pyogenic sterile arthritis,
pyoderma gangrenosum and
acne syndrome
Infevers http://fmf.igh.cnrs.fr/ISSAID/infevers/ TNFRSF1A Tumor necrosis factor
receptor-associated periodic
syndrome
IRAK4base http://bioinf.uta.fi/IRAK4base IRAK4 IRAK4 deficiency
ITGB2base http://bioinf.uta.fi/ITGB2base ITGB2 Leukocyte adhesion deficiency I
(LAD-I)
JAK3base http://bioinf.uta.fi/JAK3base JAK3 Jak3 deficiency
LIG1base http://bioinf.uta.fi/LIG1base LIG1 DNA ligase I deficiency
LIG4base http://bioinf.uta.fi/LIG4base LIG4 LIG4 syndrome
LRRC8Abase http://bioinf.uta.fi/LRRC8Abase LRRC8A Non-Bruton type autosomal
dominant agammaglobulinemia
LYSTbase http://bioinf.uta.fi/LYSTbase LYST Chediak–Higashi syndrome
MAPBPIPbase http://bioinf.uta.fi/MAPBPIPbase MAPBPIP Endosomal adaptor protein p14
deficiency
MASP2base http://bioinf.uta.fi/MASP2base MASP2 MASP2 deficiency
MLPHbase http://bioinf.uta.fi/MLPHbase MLPH Griscelli syndrome, type 3 (GS3)
MPObase http://bioinf.uta.fi/MPObase MPO Myeloperoxidase deficiency
MRE11Abase http://bioinf.uta.fi/MRE11Abase MRE11A Ataxia-telangiectasia-like disorder
(ATLD)
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CTSC Papillon Lefevre syndrome
MYO5Abase http://bioinf.uta.fi/MYO5Abase MYO5A Griscelli syndrome, type 1 (GS1)
NCF1base http://bioinf.uta.fi/NCF1base NCF1 Autosomal recessive p47phox
deficiency
NCF2base http://bioinf.uta.fi/NCF2base NCF2 Autosomal recessive p67phox
deficiency
NFKBIAbase http://bioinf.uta.fi/NFKBIAbase NFKBIA Autosomal dominant anhidrotic
ectodermal dysplasia and T-cell
immunodeficiency
NHEJ1base http://bioinf.uta.fi/NHEJ1base NHEJ1 Combined immunodeficiency
(CID) associated with micro-
cephaly and increased cellular
sensitivity to IR
NPbase http://bioinf.uta.fi/Npbase NP PNP deficiency
NRASbase http://bioinf.uta.fi/NRASbase NRAS Autoimmune lymphoproliferative
syndrome type IV
ORAI1base http://bioinf.uta.fi/ORAI1base ORAI1 Severe combined
immunodeficiency
OSTM1base http://bioinf.uta.fi/OSTM1base OSTM1 Autosomal recessive osteopetrosis
PIK3R1base http://bioinf.uta.fi/PIK3R1base PIK3R1 Pathogenic mutations in the p85a
SH2 domain
PRF1base http://bioinf.uta.fi/PRF1base PRF1 Familial haemophagocytic
lymphohistiocytosis, type II
(FHL2)
PTPN11base http://bioinf.uta.fi/PTPN11base PTPN11 Pathogenic mutations in the
SHP-2 SH2 domain
PTPRCbase http://bioinf.uta.fi/PTPRCbase PTPRC CD45 deficiency
RAB27Abase http://bioinf.uta.fi/RAB27Abase RAB27A Griscelli syndrome, type 2 (GS2)
RAC2base http://bioinf.uta.fi/RAC2base RAC2 Neutrophil immunodeficiency
syndrome
RAG1base http://bioinf.uta.fi/RAG1base RAG1 RAG1 deficiency
RAG2base http://bioinf.uta.fi/RAG2base RAG2 RAG2 deficiency
RASA1base http://bioinf.uta.fi/RASA1base RASA1 Pathogenic mutations in the
RasGAP SH2 domain
RASGRP2base http://bioinf.uta.fi/RASGRP2base RASGRP2 Leukocyte adhesion deficiency III
RFX5base http://bioinf.uta.fi/RFX5base RFX5 MHCII promoter X box regulatory
factor 5 deficiency
RFXANKbase http://bioinf.uta.fi/RFXANKbase RFXANK Ankyrin repeat containing
regulatory factor X-associated
protein deficiency







>10 000 multiple tissues and histologies
SBDSbase http://bioinf.uta.fi/SBDSbase SBDS Shwachman–Diamond syndrome
SERPING1base http://bioinf.uta.fi/SERPING1base SERPING1 Hereditary angioedema
SH2base http://bioinf.uta.fi/SH2base SH2 Pathogenic SH2 domain
mutations
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Database URL Gene(s) Diseases Remark
SH2D1Abase http://bioinf.uta.fi/SH2D1Abase SH2D1A X-linked lymphoproliferative
syndrome (XLP)
SLC35C1base http://bioinf.uta.fi/SLC35C1base SLC35C1 Leukocyte adhesion deficiency I I
(LAD-II)
SMARCAL1base http://bioinf.uta.fi/SMARCAL1base SMARCAL1 Schimke immuno-osseous
dysplasia
SP110base http://bioinf.uta.fi/SP110base SP110 Hepatic veno-occlusive disease
with immunodeficiency
syndrome (VODI)
SPINK5base http://bioinf.uta.fi/SPINK5base SPINK5 Netherton syndrome
STAT1base http://bioinf.uta.fi/STAT1base STAT1 STAT1 deficiency
STAT3base http://bioinf.uta.fi/STAT3base STAT3 Hyper-IgE syndrome
STAT5Bbase http://bioinf.uta.fi/STAT5Bbase STAT5B Growth hormone insensitivity
with immunodeficiency
STX11base http://bioinf.uta.fi/STX11base STX11 Familial haemophagocytic
lymphohistiocytosis 4
TAP1base http://bioinf.uta.fi/TAP1base TAP1 TAP1 deficiency
TAP2base http://bioinf.uta.fi/TAP2base TAP2 TAP2 deficiency
TAPBPbase http://bioinf.uta.fi/TAPBPbase TAPBP Tapasin deficiency
TAZbase http://bioinf.uta.fi/TAZbase TAZ Barth syndrome
TCIRG1base http://bioinf.uta.fi/TCIRG1base TCIRG1 Autosomal recessive osteopetrosis
(arOP)
TCN2base http://bioinf.uta.fi/TCN2base TCN2 Transcobalamin II deficiency
The Cancer Genome
Atlas (TCGA)








TLR3base http://bioinf.uta.fi/TLR3base TLR3 Influenza-associated
encephalopathy
TMC6base http://bioinf.uta.fi/TMC6base TMC6 Epidermodysplasia verruciformis
TMC8base http://bioinf.uta.fi/TMC8base TMC8 Epidermodysplasia verruciformis
TNFRSF13Bbase http://bioinf.uta.fi/TNFRSF13Bbase TNFRSF13B TACI deficiency
TYK2base http://bioinf.uta.fi/TYK2base TYK2 TYK2 deficiency





UMD-COL3A1 http://www.umd.be/COL3A1/ COL3A1 COL3A1 deficiency Restricted access
UMD-CSA http://www.umd.be/CSA/ ERCC8 ERCC8 deficiency
UMD-CSB http://www.umd.be/CSB/ ERCC6 ERCC6 deficiency
UMD-DFNB1-GJB2 http://www.umd.be/DFNB1-GJB2/ DFNB1, GJB2 DFNB1 deficiency Restricted access
UMD-DMD http://www.umd.be/DMD/ DMD DMD deficiency
UMD-DPYD http://www.umd.be/DPYD/ DPYD Dihydropyrimidine
dehydrogenase disease
Restricted access
UMD-EMD http://www.umd.be/EMD/ EMD EMD deficiency
UMD-FBN1 http://www.umd.be/FBN1/ FBN1 Marfan syndrome and
related disorders
UMD-FBN2 http://194.167.35.168/FBN2/ FBN2 Congenital contractural
arachnodactyly
(Continued)
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where to find the information they are looking for.
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